gantenerumab

This page shows the latest gantenerumab news and features for those working in and with pharma, biotech and healthcare.

Double blow to amyloid drug hopes as Roche, Lilly trial fails

At the same time, another arm of the study testing Roche’s gantenerumab also ended in failure in DIAD – also known as autosomal dominant Alzheimer’s disease (ADAD) – which accounts for ... Solanezumab works by binding to soluble amyloid beta,

Latest news

Another amyloid bust as Roche pulls crenezumab trials

Meanwhile, Roche is independently developing another amyloid-target drug called gantenerumab in phase 3, despite disappointing data in a mid-stage study.
Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

s crenezumab and Roche/Chugai’s gantenerumab.
Glimmer of hope for amyloid drugs in Alzheimer's?

Roche also had updated results from a previously-reported trial of its gantenerumab candidate that failed to show a benefit on cognition.
Biogen Idec claims first with Alzheimer's candidate

That view took a knock last December however when Roche announced it was halting a phase III trial of its gantenerumab candidate in prodromal Alzheimer's after an independent panel concluded
AB Science on track for phase III data in Alzheimer's this year

of patients, with a host of failed projects including most recently Roche's gantenerumab.

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest from PMHub

Alzheimer’s disease: reviewing the immediate treatment horizon

Crenezumab, gantenerumab, and solanezumab are all involved in additional prospective longitudinal investigations – the Alzheimer’s Prevention Initiative (Phase 2), the Dominantly Inherited Alzheimer Network study (Phase 2/3), and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.